Efficacy and Safety of Ombitasvir, Paritaprevir and Ritonavir plus Ribavirin in Hepatitis C Genotype-4 Patients on Hemodialysis | ||
| Archives of Pharmaceutical Sciences Ain Shams University | ||
| Article 1, Volume 4, Issue 2, December 2020, Pages 181-193 PDF (717.79 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/aps.2020.35940.1037 | ||
| Authors | ||
| Mai Abdelmen* 1; Nagwa Sabri2; Sara Shahin3; Ashraf Ahmed Aboubakr4 | ||
| 1Maadi Armed Forces Hospital, Cairo | ||
| 2Department of Clinical Pharmacy; Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. | ||
| 3Department of Clinical Pharmacy; Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. | ||
| 4Gastroenterology and Hepatology Department El-Maadi Armed Forces Hospital, Cairo, Egypt | ||
| Abstract | ||
| Background: The ongoing standard treatment for patients with chronic hepatitis C virus (HCV) is a mixture of direct-acting antiviral agents (DAAs). Aim of work: the aim of this study is to analyse the efficacy and safety of oral interferon-free regimen of ombitasvir, and paritaprevir with ritonavir, given with or without ribavirin (OBV/PTV/R) for chronic hepatitis C GT4 patients with or without compensated cirrhosis and experiencing long-term hemodialysis. Patients and Methods: The study was a prospective, cohort, open label trial. Fifty patients were recruited and only 47 patients completed the study. All patients were given ombitsavir 25 mg, paritaprevir 150 mg, and ritonavir 100 mg(2X50mg hard gelatin capsules) in combination with 200 mg of ribavirin daily for 12 weeks. Primary endpoints were SVR12 (HCV-RNA Results: Out of the fifty patients who contributed in the study, only forty-four (88%) patients achieved SVR12. Three patients (6%) discontinued the Qurevo; one experienced interaction with valsartan, one suffered fatigue, severe HTN, dyspnea and severe anemia and the last was infected with pneumonia. Quervo resistance rate after therapy was (6%). On the other hand, the withdrawal rate of ribavirin was 31.5% among patients who received Quervo ribavirin combination. Conclusion: A 12-week administration of OBV/PTV/R with or without RBV is highly effective with appropriate safety profile amongst GT4 hepatitis C with or without compensated cirrhosis patients with haemodialysis. | ||
| Keywords | ||
| Haemodialysis; genotype 4; hepatitis C virus; Qurevo; cirrhosis | ||
|
Statistics Article View: 501 PDF Download: 450 |
||
